b'Scientific Session Abstracts SATURDAY APRIL 20, 2024 Medication historyAspirin 112 (52.8%) 272 (48.6%) 0.291P2Y12 inhibitors 20 (9.4%) 38 (6.8%) 0.213Statins 122 (57.5%) 303 (54.1%) 0.391Beta blockers 141 (66.5%) 401 (71.6%) 0.167ACE inhibitors 95 (44.8%) 204 (36.4%) 0.033Anticoagulants 36 (17.0%) 81 (14.5%) 0.384Surgical HistoryCABG 23 (10.8%) 52 (9.3%) 0.513PCI 27 (12.7%) 68 (12.1%) 0.823CEA or CAS 9 (4.2%) 17 (3.0%) 0.406Aortic aneurysm repair 51 (24.1%) 167 (29.8%) 0.112Bypass surgery 15 (7.1%) 50 (8.9%) 0.408PVI 9 (4.2%) 39 (7.0%) 0.163Aortic surgery, open or endovascular 62 (29.2%) 205 (36.6%) 0.055Intraoperative characteristicsAnesthesia, general 199 (93.9%) 547 (97.7%) 0.009Class 1 0 1 (0.2%)Class 2 3 (1.4%) 9 (1.6%)ASA Class Class 3 70 (33.0%) 198 (35.4%) 0.925Class 4 127 (59.9%) 324 (57.9%)Class 5 12 (5.7%) 28 (5.0%)Contrast, ml 136.02 132.5997.10 0.64476.66Crystalloids, ml 1797.62 1641.82 0.0711135.84 1041.48EBL, ml 249.79 293.16 0.414603.99 678.07Fluoroscopy time, min 31.4026.38 36.71 32.27 0.020Total PRBC, units 3.019.57 2.175.74 0.230Total procedure time, min 149.1587.07 155.66 0.38595.00Number of aortic devices 2.251.00 2.120.89 0.080Discrete variables presented as numbers (%); continuous variables presented as meanstandard deviation; CVD, cerebrovascular disease; CAD, coronary artery disease; CHF, congestive heart failure, COPD, chronic obstructive pulmonary disease; DM, diabetes mellitus; HD, hemodialysis; HTN, hypertension; ACE, angiotensin-converting enzyme; CABG, coronary artery bypass graft; PCI, percutaneous coronary intervention; CEA, carotid endarterectomy; CAS, carotid artery stenting; PVI, peripheral vascular intervention; ASA, American Society of Anesthesiologists; EBL, estimated blood loss; PRBC, packed red blood cells; min, minute; ml, milliliter42 NDANNUAL MEETING|APRIL 1921, 2024|OCEANSIDE, CA 63'